全球首个可皮下注射的C5补体抑制剂在华获批 用于治疗全身型重症肌无力

Core Viewpoint - The approval of Zilucoplan sodium by the China National Medical Products Administration marks a significant advancement in the treatment of adult generalized myasthenia gravis with AChR antibody positivity, being the first and only subcutaneously injectable C5 complement inhibitor globally [1] Group 1 - The drug is intended for use in conjunction with conventional treatment options for patients suffering from this condition [1] - This approval highlights the growing importance of innovative therapies in the field of neurology and autoimmune diseases [1]